The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation

March 2, 2026 updated by: Doç.Dr.Ömer Şevgin, Uskudar University

The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation: a Randomized Controlled Trial.

The aim is to investigate the effectiveness of exercise in the treatment of erectile dysfunction and premature ejaculation.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The study was designed as a randomized controlled trial. Participants were divided into two equal groups: a control group and an exercise group. Patients in the control group were followed with normal conventional medical treatment, while participants in the exercise group underwent an 8-week, 3-day-a-week exercise program. All participants were evaluated before and after treatment using the Index of Erectile Function, the World Health Organization Quality of Life Short Form, and the Premature Ejaculation Diagnostic Tool.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria

  • Male individuals aged 25-45 years
  • Individuals diagnosed with erectile dysfunction and premature ejaculation
  • Individuals who voluntarily agree to participate in the study and sign the informed consent form
  • Individuals who have the physical and cognitive capacity to participate in pelvic floor physiotherapy applications

Exclusion Criteria

  • Individuals with a history of surgery in the pelvic region
  • Individuals with a diagnosis of neurological disease or neurological disorder that may affect pelvic floor muscle function
  • Presence of active infection, inflammation, or painful pathology in the pelvic region
  • Individuals who regularly use medications that significantly affect sexual function
  • Individuals with serious psychiatric illness or cognitive impairment that may hinder study compliance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: control group
only patients who receive medical treatment and informational training
Other: control
Patients in the control group will be followed with normal conventional medical treatment.
Other Names:
  • medical treatment
Experimental: exercise group
Patients who receive pelvic floor exercises in addition to medical treatment and education.
Other: exercise
Participants in the exercise group will undergo an 8-week, 3-day-a-week exercise program.
Other Names:
  • Pelvic Floor Exercise Group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
International Index of Erectile Dysfunction
Time Frame: 10 weeks
Mean change in International Index of Erectile Dysfunction scores. There are five specific areas addressed including Erectile Function (questions:1-5 & 15;score range: 0-5, maximum score:30); Orgasmic Function (questions:9-10; score range:0-5; maximum score:10); Sexual desire (questions:11-12; score range:1-5; maximum score:10); Intercourse satisfaction (questions:6-8; score range:0-5; maximum score:15); Overall satisfaction (questions:13-14; score range:1-5; maximum score:10). The lower the score represents greater dysfunction within each domain.
10 weeks
Premature Ejaculation Diagnostic Tool
Time Frame: 10 weeks
it was developed by Symonds et al. (2007) to better define premature ejaculation for use in clinical studies, this is a 5-point Likert-type scale consisting of 5 items. The scale was adapted to Turkish by Serefoglu et al. (2009). The highest score that can be obtained from the scale is 20.0 and the lowest score is 0.0. Scores higher than 11 are defined as "Premature Ejaculation", scores of 9-10 are defined as "possible Premature Ejaculation", and scores of eight or less are defined as "no Premature Ejaculation".
10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Uskudar University

Investigators

  • Study Chair: Parsa Keihani, Uskudar University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2026

Primary Completion (Estimated)

May 30, 2026

Study Completion (Estimated)

July 10, 2026

Study Registration Dates

First Submitted

February 25, 2026

First Submitted That Met QC Criteria

February 25, 2026

First Posted (Actual)

March 2, 2026

Study Record Updates

Last Update Posted (Actual)

March 3, 2026

Last Update Submitted That Met QC Criteria

March 2, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Uskudar93

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Erectile Dysfunction

Clinical Trials on control

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe